These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38166793)

  • 41. Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes.
    Vidyaraj CK; Chitra A; Smita S; Muthuraj M; Govindarajan S; Usharani B; Anbazhagi S
    J Epidemiol Glob Health; 2017 Dec; 7(4):289-294. PubMed ID: 29110871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trends in drug-resistant tuberculosis after the implementation of the DOTS strategy in Shenzhen, China, 2000-2013.
    Zhu L; Yang YZ; Guan HY; Cheng SM; Jin YY; Tan WG; Wu QF; Liu XL; Zhao MG; Lu ZH; Jia ZW
    Int J Tuberc Lung Dis; 2017 Jul; 21(7):759-765. PubMed ID: 28633700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thai drug-resistant tuberculosis predictive scores.
    Boonsarngsuk V; Tansirichaiya K; Kiatboonsri S
    Singapore Med J; 2009 Apr; 50(4):378-84. PubMed ID: 19421681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan.
    Farooqi JQ; Khan E; Alam SM; Ali A; Hasan Z; Hasan R
    J Pak Med Assoc; 2012 Aug; 62(8):767-72. PubMed ID: 23862246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India.
    Kumar P; Kumar P; Balooni V; Singh S
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):434-9. PubMed ID: 25859999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Isoniazid and rifampicin resistance and prior treatment for tuberculosis].
    Natal S; Valente JG; Sánchez AR; Penna ML
    Cad Saude Publica; 2003; 19(5):1277-81. PubMed ID: 14666209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.
    Ahmed S; Shukla I; Fatima N; Varshney SK; Shameem M; Tayyaba U
    Int J Mycobacteriol; 2018; 7(4):315-327. PubMed ID: 30531028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon.
    Kuaban C; Toukam LDI; Sander M
    Pan Afr Med J; 2020; 37():45. PubMed ID: 33209172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Tilahun M; Shimelis E; Wogayehu T; Assefa G; Wondimagegn G; Mekonnen A; Hailu T; Bobosha K; Aseffa A
    PLoS One; 2020; 15(8):e0236054. PubMed ID: 32750053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens.
    Noeske J; Nguenko PN
    Trans R Soc Trop Med Hyg; 2002; 96(4):429-33. PubMed ID: 12497982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome.
    Surucuoglu S; Ozkutuk N; Celik P; Gazi H; Dinc G; Kurutepe S; Koroglu G; Havlucu Y; Tuncay G
    Ann Saudi Med; 2005; 25(4):313-8. PubMed ID: 16212125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A retrospective cohort study on the treatment outcomes and genotyping of isoniazid-resistant tuberculosis patients in Eastern China.
    Li Y; Shi J; Song W; Shao Y; Zhu L; Chen C
    J Glob Antimicrob Resist; 2022 Sep; 30():335-339. PubMed ID: 35817264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment.
    Coronel J; Roper MH; Herrera C; Bonilla C; Jave O; Gianella C; Sabogal I; Huancaré V; Leo E; Tyas A; Mendoza-Ticona A; Caviedes L; Moore DA
    Clin Microbiol Infect; 2014 Jun; 20(6):536-41. PubMed ID: 24107197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR; Agarwal SK; Shah KV
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.
    Welekidan LN; Skjerve E; Dejene TA; Gebremichael MW; Brynildsrud O; Agdestein A; Tessema GT; Tønjum T; Yimer SA
    PLoS One; 2020; 15(8):e0236362. PubMed ID: 32797053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018.
    Mutayoba BK; Ershova J; Lyamuya E; Hoelscher M; Heinrich N; Kilale AM; Range NS; Ngowi BJ; Ntinginya NE; Mfaume SM; Nkiligi E; Doulla B; Lyimo J; Kisonga R; Kingalu A; Lema Y; Kondo Z; Pletschette M
    Trop Med Int Health; 2022 Oct; 27(10):891-901. PubMed ID: 36089572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.